Rapid dissemination of RET-transgene-driven melanoma in the presence of non-obese diabetic alleles: Critical roles of Dectin-1 and Nitric-oxide synthase type 2

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Dabbeche Bouricha, Emna ^a,b   Araujo, Luiza M ^a   Kato, Masashi ^c   Prévost Blondel, Armelle ^b   Garchon, Henri Jean ^a,d  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b INSTITUT COCHIN   (France)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Dectin 1; Melanoma; Myeloid cells; NOD mouse; Nos2; RET

Indexed keywords

CURDLAN; DECTIN 1; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANTIBODY LABELING; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FLOW CYTOMETRY; GENE SEQUENCE; GENETIC ASSOCIATION; IMMUNE RESPONSE; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; UVEA MELANOMA;

EID: 84965031063     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1100793     Document Type: Article

References (50)

1. J.B.Swann, M.J.Smyth. Immune surveillance of tumors. J Clin Invest 2007; 117:1137-46; PMID:17476343; http://dx.doi.org/10.1172/JCI31405
2. S.Ostrand-Rosenberg. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008; 18:11-8; PMID:18308558; http://dx.doi.org/10.1016/j.gde.2007.12.007
3. M.M.Pomerantz, M.L.Freedman. The Genetics of Cancer Risk. Cancer J 2011; 17:416-22; PMID:22157285; http://dx.doi.org/10.1097/PPO.0b013e31823e5387
4. A.Galvan, J.P.A.Ioannidis, T.A.Dragani. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 2010; 26:132-41; PMID:20106545; http://dx.doi.org/10.1016/j.tig.2009.12.008
5. H.M.Byrne. Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer 2010; 10:221-30; PMID:20179714; http://dx.doi.org/10.1038/nrc2808
6. M.Kato, M.Takahashi, A.A.Akhand, W.Liu, Y.Dai, S.Shimizu, T.Iwamoto, H.Suzuki, I.Nakashima. Transgenic mouse model for skin malignant melanoma. Oncogene 1998; 17:1885-8; PMID:9778055; http://dx.doi.org/10.1038/sj.onc.1202077
7. J.Eyles, A.L.Puaux, X.Wang, B.Toh, C.Prakash, M.Hong, T.G.Tan, L.Zheng, L.C.Ong, Y.Jin et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010; 120:2030-9; PMID:20501944; http://dx.doi.org/10.1172/JCI42002
8. R.Lengagne, S.Graff-Dubois, M.Garcette, L.Renia, M.Kato, J.G.Guillet, V.H.Engelhard, M.F.Avril, J.P.Abastado, A.Prevost-Blondel. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol 2008; 180:130-7; PMID:18097012; http://dx.doi.org/10.4049/jimmunol.180.1.130
9. V.Umansky, O.Abschuetz, W.Osen, M.Ramacher, F.Zhao, M.Kato, D.Schadendorf. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 2008; 68:9451-8; PMID:19010920; http://dx.doi.org/10.1158/0008-5472.CAN-08-1464
10. S.Kimpfler, A.Sevko, S.Ring, C.Falk, W.Osen, K.Frank, M.Kato, K.Mahnke, D.Schadendorf, V.Umansky. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 2009; 183:6330-7; PMID:19841169; http://dx.doi.org/10.4049/jimmunol.0900609
11. F.Zhao, C.Falk, W.Osen, M.Kato, D.Schadendorf, V.Umansky. Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma. Clin Cancer Res 2009; 15:4382-90; PMID:19549770; http://dx.doi.org/10.1158/1078-0432.CCR-09-0399
12. R.Lengagne, A.Pommier, J.Caron, L.Douguet, M.Garcette, M.Kato, M.F.Avril, J.P.Abastado, N.Bercovici, B.Lucas et al. T Cells Contribute to Tumor Progression by Favoring Pro-Tumoral Properties of Intra-Tumoral Myeloid Cells in a Mouse Model for Spontaneous Melanoma. PLoS One 2011; 6:e20235; PMID:21633700; http://dx.doi.org/10.1371/journal.pone.0020235
13. B.Toh, X.Wang, J.Keeble, W.J.Sim, K.Khoo, W.C.Wong, M.Kato, A.Prevost-Blondel, J.P.Thiery, J.P.Abastado. Mesenchymal Transition and Dissemination of Cancer Cells Is Driven by Myeloid-Derived Suppressor Cells Infiltrating the Primary Tumor. PLoS Biol 2011; 9:e1001162; PMID:21980263; http://dx.doi.org/10.1371/journal.pbio.1001162
14. V.Umansky, A.Sevko. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22:319-26; PMID:22349515; http://dx.doi.org/10.1016/j.semcancer.2012.02.003
15. A.Pommier, A.Audemard, A.Durand, R.Lengagne, A.Delpoux, B.Martin, L.Douguet, A.Le Campion, M.Kato, M.-F.Avril et al. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells. Proc Natl Acad Sci U S A 2013; 110:13085-90; PMID:23878221; http://dx.doi.org/10.1073/pnas.1300314110
16. M.Tham, K.W.Tan, J.Keeble, X.Wang, S.Hubert, L.Barron, N.S.Tan, M.Kato, A.Prevost-Blondel, V.Angeli et al. Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation. Oncotarget 2014; 5:12027-42; PMID:25294815; http://dx.doi.org/10.18632/oncotarget.2482
17. T.A.Dragani, B.Peissel, N.Zanesi, A.Aloisi, Y.Dai, M.Kato, H.Suzuki, I.Nakashima. Mapping of melanoma modifier loci in RET transgenic mice. Jpn J Cancer Res 2000; 91:1142-7; PMID:11092979; http://dx.doi.org/10.1111/j.1349-7006.2000.tb00897.x
18. M.A.Atkinson, E.H.Leiter. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999; 5:601-4; PMID:10371488; http://dx.doi.org/10.1038/9442
19. N.F.Bernard, F.Ertug, H.Margolese. High incidence of thyroiditis and anti-thyroid autoantibodies in NOD mice. Diabetes 1992; 41:40-6; PMID:1727738; http://dx.doi.org/10.2337/diab.41.1.40
20. T.G.Markees, D.V.Serreze, N.E.Phillips, C.H.Sorli, E.J.Gordon, L.D.Shultz, R.J.Noelle, B.A.Woda, D.L.Greiner, J.P.Mordes et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 1999; 48:967-74; PMID:10331399; http://dx.doi.org/10.2337/diabetes.48.5.967
21. D.G.Alleva, E.B.Johnson, J.Wilson, D.I.Beller, P.J.Conlon. SJL and NOD macrophages are uniquely characterized by genetically programmed, elevated expression of the IL-12(p40) gene, suggesting a conserved pathway for the induction of organ-specific autoimmunity. J Leukoc Biol 2001; 69:440-8; PMID:11261792
22. M.Prochazka, E.H.Leiter, D.V.Serreze, D.L.Coleman. Three recessive loci required for insulin-dependent diabetes in nonobese diabetic mice. Science 1987; 237:286-9; PMID:2885918; http://dx.doi.org/10.1126/science.2885918
23. J.E.Talmadge, D.I.Gabrilovich. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.org/10.1038/nrc3581
24. V.Damuzzo, L.Pinton, G.Desantis, S.Solito, I.Marigo, V.Bronte, S.Mandruzzato. Complexity and challenges in defining myeloid-derived suppressor cells: Defining Myeloid-Derived Suppressor Cells. Cytometry B Clin Cytom 2015; 88:77-91; PMID:25504825; http://dx.doi.org/10.1002/cyto.b.21206
25. M.Kato, W.Liu, A.A.Akhand, Y.Dai, M.Ohbayashi, T.Tuzuki, H.Suzuki, K.Isobe, M.Takahashi, I.Nakashima. Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I/ret transgenic mouse lines. Oncogene 1999; 18:837-42; PMID:9989837; http://dx.doi.org/10.1038/sj.onc.1202329
26. M.Kato, W.Liu, A.A.Akhand, K.Hossain, K.Takeda, M.Takahashi, I.Nakashima. Ultraviolet radiation induces both full activation of ret kinase and malignant melanocytic tumor promotion in RFP-RET-transgenic mice. J Invest Dermatol 2000; 115:1157-8; PMID:11121157; http://dx.doi.org/10.1046/j.1523-1747.2000.0202a-2.x
27. M.Kato, K.Takeda, Y.Kawamoto, T.Tsuzuki, K.Hossain, A.Tamakoshi, T.Kunisada, Y.Kambayashi, K.Ogino, H.Suzuki et al. c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res 2004; 64:801-6; PMID:14871802; http://dx.doi.org/10.1158/0008-5472.CAN-03-2532
28. M.Rusmini, P.Griseri, F.Lantieri, I.Matera, K.L.Hudspeth, A.Roberto, J.Mikulak, S.Avanzini, V.Rossi, G.Mattioli et al. Induction of RET Dependent and Independent Pro-Inflammatory Programs in Human Peripheral Blood Mononuclear Cells from Hirschsprung Patients. PLoS One 2013; 8:e59066; PMID:23527089; http://dx.doi.org/10.1371/journal.pone.0059066
29. M.S.Anderson, J.A.Bluestone. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447-85; PMID:15771578; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115643
30. H.Nishikawa, S.Sakaguchi. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1-7; PMID:24413387; http://dx.doi.org/10.1016/j.coi.2013.12.005
31. R.Roychoudhuri, R.L.Eil, N.P.Restifo. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol 2015; 33:101-11; PMID:25728990; http://dx.doi.org/10.1016/j.coi.2015.02.003
32. H.Muhl, J.Pfeilschifter. Anti-inflammatory properties of pro-inflammatory interferon-gamma. Int Immunopharmacol 2003; 3:1247-55; PMID:12890422; http://dx.doi.org/10.1016/S1567-5769(03)00131-0
33. H.Kelchtermans, A.Billiau, P.Matthys. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol 2008; 29:479-86; PMID:18775671; http://dx.doi.org/10.1016/j.it.2008.07.002
34. J.MacMicking, Q.W.Xie, C.Nathan. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15:323-50; PMID:9143691; http://dx.doi.org/10.1146/annurev.immunol.15.1.323
35. J.Y.Niederkorn. Emerging concepts in CD8+ T regulatory cells. Curr Opin Immunol 2008; 20:327-31; PMID:18406591; http://dx.doi.org/10.1016/j.coi.2008.02.003
36. A.Parodi, F.A.Battaglia, F.Kalli, F.Ferrera, G.Conteduca, S.Tardito, S.Stringara, F.Ivaldi, S.Negrini, G.Borgonovo et al. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes. Cancer Immunol Immunother 2013; 62:851-62; PMID:23359087; http://dx.doi.org/10.1007/s00262-013-1392-z
37. T.Condamine, I.Ramachandran, J.I.Youn, D.I.Gabrilovich. Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells. Annu Rev Med 2015; 66:97-110; PMID:25341012; http://dx.doi.org/10.1146/annurev-med-051013-052304
38. I.M.Dambuza, G.D.Brown. C-type lectins in immunity: recent developments. Curr Opin Immunol 2015; 32:21-7; PMID:25553393; http://dx.doi.org/10.1016/j.coi.2014.12.002
39. S.Chiba, H.Ikushima, H.Ueki, H.Yanai, Y.Kimura, S.Hangai, J.Nishio, H.Negishi, T.Tamura, S.Saijo et al. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. ELife 2014; 3:e04177; PMID:25149452; http://dx.doi.org/10.7554/eLife.04177
40. Y.Masuda, H.Inoue, H.Ohta, A.Miyake, M.Konishi, H.Nanba. Oral administration of soluble β-glucans extracted from Grifola frondosa induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice. Int J Cancer 2013; 133:108-19; PMID:23280601; http://dx.doi.org/10.1002/ijc.27999
41. J.Tian, J.Ma, K.Ma, H.Guo, S.E.Baidoo, Y.Zhang, J.Yan, L.Lu, H.Xu, S.Wang. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells: Cellular immune response. Eur J Immunol 2013; 43:1220-30; PMID:23424024; http://dx.doi.org/10.1002/eji.201242841
42. J.W.Ford, D.W.McVicar. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009; 21:38-46; PMID:19230638; http://dx.doi.org/10.1016/j.coi.2009.01.009
43. C.C.Ho, W.Y.Liao, C.Y.Wang, Y.H.Lu, H.Y.Huang, H.Y.Chen, W.K.Chan, H.W.Chen, P.C.Yang. TREM-1 Expression in Tumor-associated Macrophages and Clinical Outcome in Lung Cancer. Am J Respir Crit Care Med 2008; 177:763-70; PMID:18096709; http://dx.doi.org/10.1164/rccm.200704-641OC
44. J.Li, J, R.Salcedo, N.F.Mivechi, G.Trinchieri, A.Horuzsko. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res 2012; 72:3977-86; PMID:22719066; http://dx.doi.org/10.1158/0008-5472.CAN-12-0938
45. D.Fukumura, S.Kashiwagi, R.K.Jain. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6:521-34; PMID:16794635; http://dx.doi.org/10.1038/nrc1910
46. C.Bogdan. Nitric oxide and the immune response. Nat Immunol 2001; 2:907-16; PMID:11577346; http://dx.doi.org/10.1038/ni1001-907
47. J.Tian, J.Ma, S.Wang, J.Yan, J.Chen, J.Tong, C.Wu, Y.Liu, B.Ma, C.Mao et al. Increased expression of mGITRL on D2SC/1 cells by particulate β-glucan impairs the suppressive effect of CD4+CD25+ regulatory T cells and enhances the effector T cell proliferation. Cell Immunol 2011; 270:183-7; PMID:21636079; http://dx.doi.org/10.1016/j.cellimm.2011.05.003
48. A.G.Rothfuchs, A.Bafica, C.G.Feng, J.G.Egen, D.L.Williams, G.D.Brown, A.Sher. Dectin-1 Interaction with Mycobacterium tuberculosis Leads to Enhanced IL-12p40 Production by Splenic Dendritic Cells. J Immunol 2007; 179:3463-71; PMID:17785780; http://dx.doi.org/10.4049/jimmunol.179.6.3463
49. P.B.Simpson, M.S.Mistry, R.A.Maki, W.Yang, D.A.Schwarz, E.B.Johnson, F.M.Lio, D.G.Alleva. Cutting Edge: Diabetes-Associated Quantitative Trait Locus, Idd4, Is Responsible for the IL-12p40 Overexpression Defect in Nonobese Diabetic (NOD) Mice. J Immunol 2003; 171:3333-7; PMID:14500624; http://dx.doi.org/10.4049/jimmunol.171.7.3333
50. J.D.MacMicking, C.Nathan, G.Hom, N.Chartrain, D.S.Fletcher, M.Trumbauer, K.Stevens, Q.W.Xie, K.Sokol, N.Hutchinson et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81:641-50; PMID:7538909; http://dx.doi.org/10.1016/0092-8674(95)90085-3